<DOC>
	<DOCNO>NCT01923740</DOCNO>
	<brief_summary>To evaluate safety efficacy Absorb BVS System compare XIENCE V Everolimus Eluting Coronary Stent System ( EECSS ) treatment subject ischemic heart disease cause two de novo native coronary artery lesion separate epicardial vessel .</brief_summary>
	<brief_title>A Clinical Evaluation Absorb™ Bioresorbable Vascular Scaffold ( Absorb™ BVS ) System Chinese Population ~ ABSORB CHINA Randomized Controlled Trial ( RCT )</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Coronary Stenosis</mesh_term>
	<criteria>1 . Subject must least 18 year age time sign informed consent form . 2 . Subject legally authorize representative must provide write Informed Consent prior study related procedure . 3 . Subject must evidence myocardial ischemia ( e.g. , stable angina , unstable angina , postinfarct angina silent ischemia ) suitable elective percutaneous coronary intervention ( PCI ) . Subjects stable angina silent ischemia &lt; 70 % diameter stenosis must objective sign ischemia determine one following , echocardiogram , nuclear scan , ambulatory ECG stress ECG . In absence noninvasive ischemia , fractional flow reserve ( FFR ) must do indicative ischemia . 4 . Subject must acceptable candidate coronary artery bypass graft ( CABG ) surgery . 5 . Female subject childbearing potential plan pregnancy 1 year follow index procedure . For female subject childbearing potential , pregnancy test must perform negative result know within 14 day ( ≤14 day ) prior index procedure per site standard test . 6 . Female subject breastfeeding time screen visit breastfeed 1 year follow index procedure . 7 . Subject agree participate investigational clinical study period 1 year follow index procedure . 1 . Any surgery require general anesthesia discontinuation aspirin and/or P2Y12 inhibitor plan within 12 month index procedure . 2 . Subject know hypersensitivity contraindication device material ( cobalt , chromium , nickel , tungsten , acrylic fluoro polymer ) degradants ( everolimus , poly ( Llactide ) , poly ( DLlactide ) , lactide , lactic acid ) . Subject know contrast sensitivity adequately premedicated . 3 . Subject know allergic reaction , hypersensitivity contraindication : 1 . Aspirin ; 2 . All P2Y12 inhibitor ( include clopidogrel ticlopidine , prasugrel ticagrelor become available ) ; 3 . Heparin bivalirudin . 4 . Subject acute myocardial infarction ( AMI ) within 7 day index procedure creatine kinase ( CK ) creatine kinase myocardialband isoenzyme ( CKMB ) return within normal limit time index procedure . 5 . Subject currently experience clinical symptom consistent new onset AMI , nitrateunresponsive prolong chest pain ischemic ECG change . 6 . Subject cardiac arrhythmia identify time screen least one follow criterion meet : 1 . Subject require coumadin agent chronic oral anticoagulation . 2 . Subject likely become hemodynamically unstable due arrhythmia . 3 . Subject poor survival prognosis due arrhythmia . 7 . Subject know leave ventricular ejection fraction ( LVEF ) &lt; 30 % assessed quantitative method . LVEF may obtain within 6 month prior procedure subject stable coronary artery disease ( CAD ) . For subject present acute coronary syndrome ( ACS ) , LVEF must assess index hospitalization ( may include index procedure contrast leave ventriculography ) prior randomization order confirm subject 's eligibility . 8 . Subject receive CABG time past . 9 . Subject undergone prior PCI within target vessel last 12 month undergone prior PCI within nontarget vessel within 30 day index procedure . 10 . Subject require future stag PCI either target nontarget vessel . 11 . Subject receive solid organ transplant wait list solid organ transplant . 12 . At time screening , subject malignancy remission . 13 . Subject receive immunosuppressant therapy know immunosuppressive autoimmune disease ( e.g. , human immunodeficiency virus , systemic lupus erythematosus , etc. ) . Note : corticosteroid include immunosuppressant therapy . 14 . Subject previously receive schedule receive radiotherapy coronary artery ( vascular brachytherapy ) , chest/mediastinum . 15 . Subject receive receive chronic anticoagulation therapy ( e.g. , coumadin anticoagulation agent ) . 16 . Subject platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 . 17 . Subject know documented hepatic disorder define cirrhosis ChildPugh ≥ Class B . 18 . Subject know renal insufficiency define estimate glomerular filtration rate ( eGFR ) &lt; 30 ml/min/1.73m2 dialysis time screen . 19 . Subject high risk bleeding ; history bleed diathesis coagulopathy ; significant gastrointestinal significant urinary bleed within past six month ; refuse blood transfusion . 20 . Subject cerebrovascular accident transient ischemic neurological attack ( TIA ) within past six month prior intracranial bleed , permanent neurologic defect , know intracranial pathology ( e.g. , aneurysm , arteriovenous malformation , etc. ) . 21 . Subject extensive peripheral vascular disease precludes safe 6 French sheath insertion . Note : femoral arterial disease exclude subject radial brachial access use . 22 . Subject life expectancy &lt; 2 year noncardiac cause cardiac cause . 23 . Subject opinion Investigator designee , unable comply requirement study protocol unsuitable study reason . 24 . Subject currently participate another clinical trial yet complete primary endpoint protocolrequired medication invasive procedure . Angiographic Inclusion Criteria Assessment angiographic eligibility per visual assessment investigator qualitative quantitative variable . Online QCA recommend use appropriately sizing vessel . If online QCA use , visual estimation require . 1 . One two de novo target lesion : 1 . If one target lesion , second nontarget lesion may treat nontarget lesion must present different epicardial vessel , must treat first successful , uncomplicated result prior randomization target lesion . 2 . If two target lesion present , must present different epicardial vessel satisfy angiographic eligibility criterion . 3 . The definition epicardial vessel mean left anterior descend artery ( LAD ) , leave circumflex artery ( LCX ) , right coronary artery ( RCA ) branch . Thus , example , subject must lesion require treatment LAD diagonal branch . 2 . Target lesion must locate native coronary artery visually estimate quantitatively assess % DS ≥ 50 % &lt; 100 % thrombolysis myocardial infarction ( TIMI ) flow ≥ 1 one following : stenosis ≥ 70 % , abnormal functional test ( e.g. , fractional flow reserve , stress test ) , unstable angina postinfarct angina . 3 . Target lesion must Dmax ( online QCA ) reference vessel diameter ( RVD ) ( visual estimation ) ≥ 2.50 mm ≤ 3.75 mm ( online QCA assessment recommend ) . 4 . Target lesion must lesion length ≤ 24 mm base either visual estimation online QCA . Angiographic Exclusion Criteria All exclusion criterion apply target lesion ( ) target vessel ( ) . All exclusion criterion base visual estimation . 1 . Target lesion locate leave main . 2 . Aortoostial RCA target lesion ( within 3 mm ostium ) . 3 . Target lesion locate within 3 mm origin LAD LCX . 4 . Lesion involve bifurcation : 1 . Side branch ≥ 2 mm diameter , 2 . Side branch diameter stenosis ≥ 50 % , 3 . Side branch require protection guide wire , 4 . Side branch require predilatation 5 . Anatomy proximal within lesion may impair delivery Absorb BVS XIENCE V , include : 1 . Extreme angulation ( ≥ 90° ) proximal within target lesion 2 . Excessive tortuosity ( ≥ two 45° angle ) proximal within target lesion 3 . Moderate heavy calcification proximal within target lesion 6 . Target lesion target vessel involve myocardial bridge . 7 . Target vessel contains thrombus indicate angiographic image . 8 . Target vessel previously treat stent time prior index procedure Absorb BVS XIENCE V would need cross stent reach target lesion . 9 . Target vessel previously treat stent target lesion within 5 mm proximal previously treat lesion . 10 . Target lesion prevents complete balloon predilatation , define full balloon expansion follow outcome : 1 . Residual % DS &lt; 40 % ( per visual estimation ) , ≤ 20 % strongly recommend . 2 . TIMI Grade3 flow ( per visual estimation ) . 3 . No angiographic complication ( e.g . distal embolization , side branch closure ) . 4 . No dissection National Heart , Lung , Blood Institute ( NHLBI ) grade DF . 5 . No chest pain last &gt; 5 minute . 6 . No ST depression elevation last &gt; 5 minute .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Absorb™ BVS</keyword>
	<keyword>Angioplasty</keyword>
	<keyword>Bioabsorbable</keyword>
	<keyword>BVS</keyword>
	<keyword>Bioresorbable</keyword>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Coronary Artery Endothelial Responsiveness</keyword>
	<keyword>Coronary artery restenosis</keyword>
	<keyword>Coronary artery stenosis</keyword>
	<keyword>Coronary scaffold</keyword>
	<keyword>Coronary Stent</keyword>
	<keyword>Drug elute stent</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Myocardial ischemia</keyword>
	<keyword>Stent thrombosis</keyword>
	<keyword>Stents</keyword>
</DOC>